The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS.
The role of PI type Z heterozygotes and additional, rare variant genotypes in the gene encoding α1-antitrypsin (SERPINA1) in determining the COPD risk and severity is controversial. To comprehensively evaluate the effects of rare SERPINA1 variants on lung function and emphysema phenotypes in subjects with significant tobacco smoke exposure using deep gene resequencing and α1-antitrypsin concentrations. DNA samples from 1,693 non-Hispanic Whites, 385 African Americans, and 90 Hispanics with ≥20 pack-years smoking were resequenced for the identification of rare variants (allele frequency<0.05) in 16.9kB of SERPINA1. White PI Z heterozygotes confirmed by sequencing (MZ, N=74) had lower post-bronchodilator FEV1 (p=0.007), FEV1/FVC (p=0.003), and greater CT-based emphysema (p=0.02) compared to 1,411 Whites without PI Z, S, or additional, rare variants denoted as VR. PI Z-containing compound heterozygotes (ZS/ZVR, N=7) had lower FEV1/FVC (p=0.02) and FEF25-75% (p=0.009). 19 Whites heterozygote for five non-S/Z coding variants associated with lower α1-antitrypsin had greater CT-based emphysema compared to those without rare variants. In African Americans, a 5' untranslated region insertion (rs568223361) associated with lower α1-antitrypsin and functional small airways disease (p=0.007). In this integrative deep sequencing study of SERPINA1 with α1-antitrypsin concentrations in a heavy smoker and COPD cohort, we confirmed the effects of PI Z heterozygote and compound heterozygote genotypes. We demonstrate the cumulative effects of multiple SERPINA1 variants on α1-antitrypsin deficiency, lung function, and emphysema, thus, significantly increasing the frequency of SERPINA1 variation associated with respiratory disease in at-risk smokers.